Publication

Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied?

Haarman, B. C. M., de Boer, M. K., van der Gaag, C. M., Burger, H., Nolen, W. A. & Schoevers, R. A., Feb-2019, In : Bipolar Disorders. 21, 1, p. 13-15 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

APA

Haarman, B. C. M., de Boer, M. K., van der Gaag, C. M., Burger, H., Nolen, W. A., & Schoevers, R. A. (2019). Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied? Bipolar Disorders, 21(1), 13-15. https://doi.org/10.1111/bdi.12731

Author

Haarman, B C M ; de Boer, M K ; van der Gaag, C M ; Burger, H ; Nolen, W A ; Schoevers, R A. / Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied?. In: Bipolar Disorders. 2019 ; Vol. 21, No. 1. pp. 13-15.

Harvard

Haarman, BCM, de Boer, MK, van der Gaag, CM, Burger, H, Nolen, WA & Schoevers, RA 2019, 'Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied?', Bipolar Disorders, vol. 21, no. 1, pp. 13-15. https://doi.org/10.1111/bdi.12731

Standard

Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied? / Haarman, B C M; de Boer, M K; van der Gaag, C M; Burger, H; Nolen, W A; Schoevers, R A.

In: Bipolar Disorders, Vol. 21, No. 1, 02.2019, p. 13-15.

Research output: Contribution to journalEditorialAcademicpeer-review

Vancouver

Haarman BCM, de Boer MK, van der Gaag CM, Burger H, Nolen WA, Schoevers RA. Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied? Bipolar Disorders. 2019 Feb;21(1):13-15. https://doi.org/10.1111/bdi.12731


BibTeX

@article{e11694155020406a8dd45e1d30862b25,
title = "Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied?",
abstract = "Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50{\%} of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. In this perspective article, we will give an overview of the neuropharmacodynamics of (low-dose) aspirin, reflect on the published clinical studies and argue that aspirin is a promising, yet understudied option for recurrence prevention This article is protected by copyright. All rights reserved.",
author = "Haarman, {B C M} and {de Boer}, {M K} and {van der Gaag}, {C M} and H Burger and Nolen, {W A} and Schoevers, {R A}",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = "2",
doi = "10.1111/bdi.12731",
language = "English",
volume = "21",
pages = "13--15",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Aspirin for recurrence prevention in bipolar disorder-Promising, yet clinically understudied?

AU - Haarman, B C M

AU - de Boer, M K

AU - van der Gaag, C M

AU - Burger, H

AU - Nolen, W A

AU - Schoevers, R A

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50% of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. In this perspective article, we will give an overview of the neuropharmacodynamics of (low-dose) aspirin, reflect on the published clinical studies and argue that aspirin is a promising, yet understudied option for recurrence prevention This article is protected by copyright. All rights reserved.

AB - Current available maintenance pharmacotherapy for bipolar disorder (BD) leaves ample room for improvement. Up to 50% of patients with BD do not respond adequately to available treatments and still suffer from manic and/or depressive episodes. In this perspective article, we will give an overview of the neuropharmacodynamics of (low-dose) aspirin, reflect on the published clinical studies and argue that aspirin is a promising, yet understudied option for recurrence prevention This article is protected by copyright. All rights reserved.

U2 - 10.1111/bdi.12731

DO - 10.1111/bdi.12731

M3 - Editorial

VL - 21

SP - 13

EP - 15

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 1

ER -

ID: 71933513